---

Ventilator-Associated Pneumonia (VAP)

MD Anaesthesia PG Examination - 30 Marks Answer

---

1. DEFINITION

• Early-onset VAP: occurs within the first 48-72 hours of intubation
• Late-onset VAP: occurs after 72 hours (>5 days of hospitalization in some classifications)

---

2. INCIDENCE AND EPIDEMIOLOGY

• VAP occurs in up to 10-40% of intubated patients; it is the most frequent ICU-acquired infection and most frequent ventilator-associated complication
• Peak incidence: 5-9 days after intubation; cumulative risk is proportional to duration of ventilation
• Incidence using NHSN criteria: <4% per mechanical ventilation episode (reflecting improved prevention practices)
• VAP accounts for approximately 35% of all hospital-acquired pneumonia cases
• With COVID-19, incidence has again increased in mechanically ventilated patients
• On any given ICU day, ~10% of patients have pneumonia - VAP in the overwhelming majority

---

3. PATHOGENESIS

Specific Mechanisms:

---

4. MICROBIOLOGY

Non-MDR (Core) Pathogens - typically Early-Onset VAP:

• Streptococcus pneumoniae
• Haemophilus influenzae
• Methicillin-sensitive Staphylococcus aureus (MSSA)
• Antibiotic-sensitive Enterobacteriaceae (E. coli, Klebsiella pneumoniae, Proteus spp., Enterobacter spp., Serratia marcescens)

MDR Pathogens - typically Late-Onset VAP:

• Pseudomonas aeruginosa (most important; dual-drug coverage often required)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Acinetobacter baumannii (may be susceptible only to polymyxins)
• ESBL-producing strains
• Carbapenem-resistant Enterobacteriaceae
• Legionella pneumophila, Burkholderia cepacia

---

5. RISK FACTORS

Patient Factors:

• Advanced age, immunocompromised state, malnutrition
• COPD, ARDS, high APACHE-II score
• Reduced level of consciousness

Treatment/Procedure-Related Factors:

• Duration of mechanical ventilation (most important risk factor)
• Supine positioning
• Nasogastric/nasotracheal tubes (sinusitis predisposition)
• Continuous IV sedation (reduces ability to clear secretions)
• Prior intravenous antibiotic use within 90 days (strongest risk factor for MDR)
• Presence of septic shock; ARDS before VAP onset
• Acute renal replacement therapy before VAP

For MDR Pathogens specifically:

1. Prior IV antibiotic use within 90 days
2. Presence of septic shock
3. ARDS before VAP
4. ≥5 days of hospitalization before VAP onset
5. Acute renal replacement therapy before VAP

---

6. CLINICAL FEATURES AND DIAGNOSIS

Clinical Criteria:

• New or progressive infiltrate on chest radiograph
• Plus at least 2 of the following:
  • Fever (>38.5°C) or hypothermia (<36°C)
  • Leukocytosis (>10,000/mm³) or leukopenia (<4,000/mm³)
  • Purulent tracheobronchial secretions (change in color/consistency)
  • Deterioration in oxygenation (↑FiO₂ requirement, ↑PEEP)

Important caveat: Radiographic findings alone are insufficient - pulmonary edema, atelectasis, ARDS, and pulmonary contusion can mimic VAP on CXR.

Clinical Pulmonary Infection Score (CPIS):

Microbiologic Diagnosis:

• Endotracheal aspirate (quantitative culture: threshold ≥10⁶ CFU/mL)
• Blood cultures (positive in ~15% of VAP cases)

• Bronchoalveolar lavage (BAL): threshold ≥10⁴ CFU/mL; intracellular organisms seen in >5% of cells = positive
• Protected Specimen Brush (PSB): threshold ≥10³ CFU/mL
• Blind bronchial sampling as alternative if bronchoscopy unavailable

---

7. PREVENTION - THE VAP BUNDLE

Core Bundle Elements:

Additional Prevention Measures:

• Avoid unnecessary sedation - use lowest effective dose
• Early mobilization - reduces ventilator days
• Silver-coated endotracheal tubes - NOT proven beneficial despite theoretical rationale
• Sucralfate vs. acid-suppression: Acid suppression (PPIs/H2 blockers) raises gastric pH → bacterial overgrowth → increased VAP risk; sucralfate maintains acid barrier; reserve acid suppression for high-risk GI bleeding patients
• Noninvasive ventilation (NIV) where possible - eliminates ETT-related risk entirely
• Prophylactic antibiotics: 2 days of IV amoxicillin-clavulanate in post-cardiac-arrest patients on targeted hypothermia reduces early VAP by ~45%

---

8. TREATMENT

General Principles:

• Do not delay treatment - start antibiotics after culture specimens are collected; delay increases mortality
• De-escalation strategy: Start broad, then narrow spectrum based on culture results at 48-72 hours
• Antibiotic selection based on local antibiogram (hospital-specific resistance patterns)
• Duration: 7-8 days (vs. longer courses) is recommended for most VAP - shorter courses reduce resistance without increasing failure rates

Early-Onset VAP (without MDR risk factors):

Late-Onset VAP / MDR Risk Factors:

• Antipseudomonal cephalosporin: Ceftazidime 2 g IV q8h, or Cefepime 1-2 g q8-12h; newer: ceftazidime/avibactam 2.5 g q8h, ceftolozane/tazobactam 3 g q8h
• Antipseudomonal carbapenem: Meropenem 1 g q8h, Imipenem 500 mg q6h
• Piperacillin-tazobactam 4.5 g IV q6h

• Vancomycin 15-20 mg/kg IV q8-12h (monitor troughs; target 10-15 mcg/mL)
• Linezolid 600 mg IV/PO q12h - preferred over vancomycin in renal insufficiency and high-MIC MRSA isolates (15% more efficacious than adjusted-dose vancomycin)

Indications for MRSA Coverage:

1. Prior IV antibiotic use within 90 days
2. ICU where >10-20% of S. aureus isolates are methicillin-resistant
3. Unit where MRSA prevalence is unknown
4. Known MRSA carrier
5. Severely ill patient at high risk of mortality

For Acinetobacter baumannii:

• Carbapenem or ampicillin-sulbactam for susceptible strains
• Polymyxin B or Colistin for pan-resistant strains
• Inhaled colistin may be added as adjunct

For Pseudomonas aeruginosa:

• Combination therapy recommended (40-50% failure rate with any single regimen)
• Consider prolonged/continuous infusion of beta-lactams to optimize pharmacodynamics
• Biofilm on ETT allows persistence - early ETT change may be considered in refractory cases

---

9. COMPLICATIONS

• Increased mortality: Crude mortality 30-70%; attributable mortality ~5-25% (VAP with COVID-19 has higher attributable mortality)
• Prolonged mechanical ventilation: Most important consequence - each additional day on ventilator increases risk of further complications
• Increased ICU and hospital length of stay
• Necrotizing pneumonia (P. aeruginosa, S. aureus): pulmonary hemorrhage, empyema
• Long-term: bronchiectasis, parenchymal scarring, recurrent pneumonia
• Nutritional depletion - catabolic state worsens outcomes
• Treatment failure - especially with MRSA (40% clinical failure with standard vancomycin) and Pseudomonas (40-50% failure regardless of regimen)

---

10. PROGNOSIS AND MONITORING

• Clinical improvement (especially oxygenation) expected within 48-72 hours of appropriate therapy
• Chest radiographic findings often worsen initially - less reliable than clinical/oxygenation parameters for response assessment
• Procalcitonin has a role in guiding duration of therapy alongside clinical response
• Serial quantitative cultures clarify microbiologic response

Biomarkers used in monitoring VAP:

• Procalcitonin (PCT) - guides antibiotic de-escalation and duration
• C-reactive protein (CRP)
• Serial CPIS scoring

---

SUMMARY TABLE

---